Peptide Antibiotics Market Report Scope & Overview:

The Peptide Antibiotics Market was valued at USD 5.35 Billion in 2025 and is expected to reach USD 8.83 Billion by 2035, growing at a CAGR of 5.14% from 2026–2035.

Market growth for peptide antibiotics remains consistent due to the rising cases of antimicrobial resistance and the urgent need for newer drugs. This is because peptide antibiotics have wide antimicrobial activity and pose less resistance compared to traditional antibiotics. The main mode of action of peptides is targeting the microbial cell membrane and hence bypassing all the resistance mechanisms encountered by the traditional antibiotics, since the microbes will have to restructure their membrane structure completely in order to develop resistance, something that is very unlikely within normal clinical timelines.

In July 2024, the CDC published its report on antimicrobial resistance threats in the United States for 2021 through 2022, finding that six categories of hospital-onset bacterial antimicrobial-resistant infections grew by a combined 20% during the COVID-19 pandemic years relative to before the pandemic, reaching an all-time high in 2021 and remaining elevated through 2022. The report also documented an almost five-fold increase in reported clinical cases of Candida auris, a drug-resistant yeast that spreads within healthcare facilities and can lead to serious illness, between 2019 and 2022.

Market Size and Forecast

• Market Size in 2026E: USD 5.63 Billion

• Market Size by 2035: USD 8.83 Billion

• CAGR: 5.14% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

Peptide Antibiotics Market Trends

• Advances in peptide engineering and non-ribosomal synthesis technologies are accelerating the development of novel antibiotics against multidrug-resistant bacterial infections.

• Improved peptide synthesis methods are reducing manufacturing costs while enhancing scalability, purity, and commercial viability of peptide antibiotic production.

• Injectable peptide antibiotics continue to dominate severe infection treatment, while innovations in oral delivery systems are expanding outpatient therapeutic applications.

• Growing adoption of online pharmacy platforms is improving patient access to peptide antibiotics, especially in underserved and remote healthcare markets.

• Rising government funding and global antimicrobial resistance initiatives are driving research, clinical development, and commercialization of next-generation peptide antibiotics.

The U.S. Peptide Antibiotics Market Outlook

The U.S. Peptide Antibiotics Market was valued at approximately USD 2.04 Billion in 2025 and is expected to reach approximately USD 3.29 Billion by 2035, growing at a CAGR of approximately 4.92%.

The United States is the dominant market for peptide antibiotics in North America, due to superior research & development capabilities within pharmaceutical companies, an effective regulatory framework, and investments aimed at fighting resistance to antimicrobials. As per the estimates provided by CDC, there are more than 2.8 million cases of antimicrobial resistant infections annually reported in the United States, which keeps driving the need for therapies that can work effectively against such resistant microbes.

Tyzavan, a new formulation of vancomycin, a glycopeptide antibiotic that is used to treat septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections in adults and children, received approval from the FDA in July 2025. This indicates that the agency remains actively involved in the development of antibiotic formulations using peptides in order to increase their ease of administration.

Peptide Antibiotics Market Segment Analysis

• By Product, the non-ribosomal synthesized peptide antibiotics segment dominated the peptide antibiotics market with a 72.16% revenue share in 2025, while the ribosomally synthesized peptide antibiotics segment is expected to demonstrate the fastest growth.

• By Disease, the skin infection segment dominated the peptide antibiotics market with a 36.22% revenue share in 2025, while the blood stream infections segment is the fastest growing with a CAGR of approximately 5.77%.

• By Route of Administration, the injectable segment dominated the peptide antibiotics market with a 44.18% revenue share in 2025, while the oral segment is expected to register the highest growth.

• By Distribution Channel, the hospital pharmacies segment dominated the peptide antibiotics market with a 42.13% revenue share in 2025, while the online pharmacies segment is expected to experience the fastest growth.

By Product, non-ribosomal synthesized peptides dominate, ribosomally synthesized peptides grows fastest

Non-ribosomal synthesized peptide antibiotics dominated the market with 72.16% share in 2025, owing to their extensive activity and increased stability relative to ribosomally synthesized peptides. Non-Ribosomal Peptides, formed by the modular enzyme system, facilitate the synthesis of diverse and potent antibiotics with reduced issues related to drug resistance, especially those bacteria that have become resistant to multiple drugs.

Ribosomally synthesized peptide antibiotics are expected to exhibit the fastest growth over the forecast period. The ribosomal peptides are generated through the ribosome itself and are often simpler and more economical to produce compared to non-ribosomal peptides. The development in technology of peptide production and research done on their anti-microbial properties is expected to boost their demand in the coming years due to increased antimicrobial resistance.

By Disease, skin infection dominates, bloodstream infections grow fastest

Skin infection led the peptide antibiotics market with a 36.22% share in 2025, driven by the substantial volume of bacterial skin infections, including impetigo and cellulitis, requiring effective antimicrobial therapy. Peptide antibiotic produced by non-ribosomal synthesis, especially, has proven to be very effective against resistant strains like MRSA, which is the leading cause of skin infections, and the increased realization about the weaknesses of conventional antibiotics makes this category even more dominant.

Antibiotics for bloodstream infection are expected to display the fastest growth rate, registering a projected CAGR of about 5.77% through the forecast period due to increasing cases of bacterial infections which are multidrug resistant. Bloodstream infections such as sepsis require prompt treatment, and the effectiveness of peptide-based antibiotics in treating such infections cannot be underestimated.

By Route of Administration, injectable dominates, oral grows fastest

Peptide antibiotics that were delivered in the form of injectables accounted for 44.18% of the total peptide antibiotics market share in 2025 due to increased effectiveness and rapid onset of action, especially in cases of severe infections. Injectable forms of peptide antibiotics continue to be widely used in hospitals for treating systemic and severe infections such as bloodstream infections and hospital-acquired infections.

It is anticipated that oral preparations will witness the highest growth during the forecasted period, due to rising demand for more convenient, affordable, and patient-friendly therapies. The ease of administration of oral peptide antibiotics makes them very popular among patients and healthcare professionals alike. Advances in oral delivery technology that increase their stability and bioavailability are also responsible for the high growth rate of the segment.

By Distribution Channel, hospital pharmacies dominate, online pharmacies grow fastest

The largest segment belonged to hospital pharmacies which occupied a share of 42.13%, owing to the important contribution of hospitals to the treatment of serious and complicated infections. The drugs of the peptide antibiotics category are mainly prescribed in the treatment of serious infections where other treatments are not effective and can be administered in hospital premises, especially for patients with hospital acquired infections or bloodstream infections.

Online pharmacies are anticipated to experience the fastest growth during the forecast period, driven by the increasing adoption of e-commerce business models and consumer preference for convenient home drug delivery. Growing awareness of peptide antibiotics and demand for alternative drug therapies against infection-resistant strains continue to make online pharmacies a relatively more accessible option for patients in regions with limited healthcare infrastructure.

Regional Analysis

North America Peptide Antibiotics Market Insights

North America held the leading position in the peptide antibiotics market in 2025, with a share of 42.23%, as the region possessed highly developed healthcare infrastructure, had numerous major pharma companies operating there, and made significant investments in antibiotic R&D. The growth is facilitated by government initiatives and programs that encourage investment in the development of methods of countering antibiotic resistance.

The high level of understanding by the doctors and other healthcare professionals, together with the existence of an effective regulatory framework, allows for rapid availability of the new antibiotics and quick scaling up. The United Nations General Assembly endorsed the resolution A/RES/76/257 in March 2022, which calls for the second High-level meeting on antimicrobial resistance, set for 2024, backed by the Quadripartite Organizations and the Global Leaders Group.

Europe Peptide Antibiotics Market Insights

Europe is a leading region in the global peptide antibiotics market due to the strength of its pharmaceuticals industry, high expenditure on research and development, and its active effort to counter the growing resistance to antimicrobials. Innovation in peptides is spearheaded by Germany and France because of the supportive regulatory framework in place.

Germany occupies the top spot in the peptides antibiotic segment of the European market, attributed to its well-developed pharmaceutical infrastructure, high research & development spending, and regulatory policies against antimicrobial resistance. Germany has seen a significant increase in bacterial infections such as those occurring on the skin and blood stream, leading to the increased need for efficacious peptide antibiotics.

Asia Pacific Peptide Antibiotics Market Insights

Asia Pacific is the fastest-growing region in the peptide antibiotics market, with a projected CAGR of 6.10% over the forecast period, owing to growing infectious disease burdens and mounting rates of antimicrobial resistance in countries including China and India. The region continues to see increasing healthcare access, high urbanization rates, and increased investment in pharmaceutical R&D.

Favorable government initiatives, combined with a substantial rise in generic and biosimilar manufacturing facilities, continue to drive peptide antibiotic development and adoption across the region. As regional healthcare infrastructure continues to mature and antimicrobial resistance awareness expands, Asia Pacific is positioned to sustain its lead as the fastest-growing peptide antibiotics market throughout the forecast period.

MEA & Latin America Peptide Antibiotics Market Insights

The Latin American peptide antibiotics market is currently witnessing steady growth due to heightened awareness about antimicrobial resistance, rising investments within the healthcare industry, and developing pharmaceutical infrastructure in countries such as Brazil and Mexico. However, economic differences, lack of adequate healthcare in rural areas, and different regulatory environments act as growth inhibitors.

The Middle East and Africa region is seeing consistent growth due to the advancements in healthcare facilities in the countries of South Africa and Saudi Arabia as well as the growing importance being placed on the treatment of resistant infections. Although non-ribosomal synthesized peptide antibiotics have been gaining popularity in this region, financial limitations continue to hinder their growth.

Market Dynamics

Growth Drivers: Rising antimicrobial resistance accelerates demand for novel therapeutics

Antibiotic resistance is one of the most serious global health challenges facing the world today. According to the CDC, more than 2.8 million cases of antimicrobial-resistant infections take place in the U.S. each year. As such, there is increased need for newer methods of treatment that can counter resistant bacteria due to their ability to become resistant to available antibiotics. Peptide antibiotics have come out as an innovative approach in overcoming antibiotic resistance due to the nature of their operation in destabilizing the bacteria membrane among other actions.

Rising prevalence of hospital-acquired infections, including bloodstream infections, pneumonia, and surgical site infections, further compounds this driver. The CDC estimates that approximately 1 in 31 hospitalized patients experiences at least one healthcare-associated infection daily, with these infections causing approximately 722,000 infections and 75,000 deaths annually in the United States alone. Peptide antibiotics, particularly in injectable form, remain a critical tool for addressing these life-threatening infections given their broad-spectrum activity and rapid onset of action.

Restraints: High production costs and manufacturing complexity restrict market growth

Peptide antibiotics demand a highly sophisticated process of production which is quite complicated and dependent on technology, thereby making their production very costly and limiting large-scale production capacity especially for smaller firms. Such high costs have direct repercussions on the pricing and reimbursement process of such products especially in price sensitive countries.

The broader antibiotic pipeline faces a severe access and development crisis, with woefully insufficient research and development activity to keep pace with rising antimicrobial resistance. According to the World Bank, antimicrobial resistance is predicted to lead to additional healthcare costs of up to USD 1 trillion in 2050, in addition to global losses in gross domestic product from USD 1 trillion to USD 3.4 trillion per year by 2030.

Opportunities: Growing global AMR mitigation investment presents substantial growth potential

There is tremendous hope that the continuous efforts made by government agencies and international organizations toward antimicrobial resistance will benefit the peptide antibiotics makers. Programs such as those sponsored by CDC and BARDA, and others such as the global programs as a result of UN General Assembly High-Level Meetings on Antimicrobial Resistance, are in place for innovation in peptide drugs.

Future improvements in the technology for manufacturing peptides, along with increasing awareness of the distinct action mechanisms that make peptides antibiotics resistant to bacteria, present great opportunities for manufacturers to achieve significant market growth amid the antimicrobial resistance problem faced by the world's health care systems. The fact that the production costs of ribosomal peptides will continue decreasing makes the expansion of access to these drugs an actual possibility.

Recent Developments:

• 2024: Ceftobiprole medocaril sodium, a fifth-generation cephalosporin with peptide-adjacent glycopeptide-class relevance, gained expanded approval in 2024 for skin and skin structure infections, S. aureus bacteremia, and community-acquired pneumonia, broadening treatment options against MRSA and Pseudomonas aeruginosa.

• 2025: In February 2025, the Novo Nordisk Foundation launched its Catalyst Grants program to accelerate innovation and rapid testing of novel ideas across three focus areas, including antimicrobial resistance, invasive pathogenic fungi, and innate immunity against airborne viral infections.

• 2025: In July 2025, the FDA approved Tyzavan, a ready-to-infuse, room-temperature stable formulation of the glycopeptide antibiotic vancomycin, indicated for adult and pediatric patients with septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections.

Peptide Antibiotics Market key players are:

• Pfizer Inc.

• Teva Pharmaceutical Industries Ltd.

• Bachem Holding AG

• Sandoz Group AG

• PolyPeptide Group

• Melinta Therapeutics

• Merck & Co., Inc.

• Xellia Pharmaceuticals ApS

• Cubist Pharmaceuticals

• Paratek Pharmaceuticals, Inc.

• Entasis Therapeutics

• Spero Therapeutics, Inc.

• Nabriva Therapeutics plc

• Venatorx Pharmaceuticals, Inc.

• Allecra Therapeutics GmbH

• Basilea Pharmaceutica Ltd.

• Debiopharm International SA

• Recce Pharmaceuticals Ltd.

• Innoviva Specialty Therapeutics, Inc.

• Cumberland Pharmaceuticals Inc.

Peptide Antibiotics Market Report Scope: